FDA Issues Emergency Approval To Lilly's Arthritis Drug With Remdesivir For COVID-19 Treatment

FDA Issues Emergency Approval To Lilly's Arthritis Drug With Remdesivir For COVID-19 Treatment

RTTNews

Published

The U.S. Food and Drug Administration issued an emergency use authorization for Eli Lilly and Co.'s (LLY) rheumatoid arthritis drug baricitinib, in combination with Gilead Sciences' (GILD) remdesivir, to treat COVID-19 patients.

Full Article